This week on LATAM MedTech Insights, we dive into the seismic shift in Brazil's digital health market. ANVISA just launched its 'Agiliza-IA' program, promising to approve AI-powered diagnostic software in a record 90 days. This could unlock one of the largest markets in Latin America for SaMD innovators.

But there's a catch. While the speed is tempting, the program introduces formidable new barriers. Consider a European company with a market-leading AI tool. They're ready to enter Brazil, but now face an unexpected demand for clinical trials conducted exclusively on Brazilian patients. This single requirement could delay their entry by a year and cost millions. Is the fast-track worth the price?

Key Takeaways:

- What exactly is ANVISA's new "Agiliza-IA" program?

- Why are the new local clinical data requirements a game-changer for foreign companies?

- What are the specific cybersecurity protocols you must now meet for approval?

- How did a local startup beat global giants to the first approval?

- Is Brazil's 90-day promise a real opportunity or a hidden trap?

- What does this mean for the future of MedTech regulation across LATAM?

- How can you start preparing your technical dossier for this new pathway today?

At Pure Global, we specialize in turning these regulatory puzzles into market access victories. We offer end-to-end consulting for MedTech and IVD companies, leveraging local expertise and advanced AI tools to streamline your entry into over 30 global markets, including Brazil. Don't let complex regulations be a barrier to your growth. Contact Pure Global at [email protected] or visit us at https://pureglobal.com/ to learn how we can accelerate your journey.